The relation of the immune system with cancer is known for many decades. Harnessing the host immune response to specifically target tumor cells holds promise as a strategy to fight cancer. Although the potential of this strategy remains solid, the approach still requires optimization. Current approaches in cancer immunotherapy include the use of antibodies, cytokines, tumor antigen vaccines, dendritic cells, T cells and NK cells.
So far "passive" immunotherapy has experienced the greatest success, with antibody and cytokine therapies leading the way and being already established in the clinical setting.
|Name of drug||Type of cancer it treats|
|Alemtuzumab (Campath)||Chronic lymphocytic leukemia|
|Bevacizumab (Avastin)|| Brain cancer
|Cetuximab (Erbitux)|| Colon cancer
Head and neck cancers
|Ibritumomab (Zevalin)||Non-Hodgkin's lymphoma|
|Ofatumumab (Arzerra)||Chronic lymphocytic leukemia|
|Panitumumab (Vectibix)||Colon cancer|
|Rituximab (Rituxan)|| Chronic lymphocytic leukemia
|Tositumomab (Bexxar)||Non-Hodgkin's lymphoma|
|Trastuzumab (Herceptin)|| Breast cancer